A methylene blue-assisted technique for harvesting lymph nodes after radical surgery for gastric cancer: a prospective, randomized, controlled study

What Was Tested

Researchers studied Methylene blue (non-peptide stack partner) in this randomized controlled trial publication.

Harvesting lymph nodes (LNs) after gastrectomy is essential for accurate staging.

This trial evaluated the efficiency and quality of a conventional method and a methylene blue-assisted method in a randomized manner.

Who Took Part

According to the abstract, 2012, patients were involved.

The age groups tagged for this paper are adults, middle-aged adults, older adults and people over 80, both men and women.

Between August 2012 and December 2012, 60 patients were assigned to undergo treatment using the conventional method (n=29) and the methylene blue dye method (n=31).

How the Study Was Run

The researchers set it up as a randomized study.

The patients were allocated by chance, so the Methylene blue (non-peptide stack partner) group and the comparison group should start out alike.

What Was Measured

This trial evaluated the efficiency and quality of a conventional method and a methylene blue-assisted method in a randomized manner.

The secondary endpoint was the number of harvested LNs, as a quality measure.

Topics PubMed links to this paper include Adenocarcinoma, Coloring Agents, Lymph Node Excision, Lymphatic Metastasis, Methylene Blue, Neoplasm Staging and Stomach Neoplasms.

What This Means in Plain Language

The paper is a randomized study of Methylene blue (non-peptide stack partner) in 2012, patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2015 (The American journal of surgical pathology), a journal based in United States.

More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.